



**Eitan Amir**

**Contact**

Eitan Amir

## Publications (18)

Adam R, Tibau A, Molto Valiente C, Seruga B, Ocana A, Amir E, Templeton A. Clinical benefit of cancer drugs approved in Switzerland 2010–2019. *PLoS one* 2022; 17:e0268545.

Adam R, Diez-Gonzalez L, Ocana A, Seruga B, Amir E, Templeton A. Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. *Exp Mol Pathol* 2017; 102:455–474.

Ocana A, Pandiella A, Andrés-Pretel F, Seruga B, Corrales-Sanchez V, Serrano-Heras G, Gascon-Escribano M, Vera-Badillo F, Templeton A, Garcia-Olmo D, Diez-Gonzalez L, Amir E. Circulating DNA and survival in solid tumors. *Cancer Epidemiol Biomarkers Prev* 2015

Ocana A, Pandiella A, Niraula S, Seruga B, Vera-Badillo F, Templeton A, Gascón-Escribano M, Srikanthan A, Corrales-Sanchez V, Diez-Gonzalez L, Ethier J, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. *Oncotarget* 2015

Vera-Badillo F, Tannock I, Bedard P, Goldstein R, Seruga B, Templeton A, Ocana A, Kuruzar G, Chang M, Amir E. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. *J Clin Pathol* 2015

Templeton A, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond G, Tannock I. Influence of censoring on conclusions of trials for women with metastatic breast cancer. *Eur J Cancer* 2015

Tibau A, Barnadas A, Seruga B, Ocana A, Templeton A, Vera-Badillo F, Ethier J, Srikanthan A, Bedard P, Amir E. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. *J Clin Oncol* 2014; 33:100–6.

Templeton A, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordán J, Amir E, Pandiella A, Ocana A. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. *Cancer Treat Rev* 2014; 40:1048–55.

Vera-Badillo F, Ocana A, Templeton A, Tibau A, Amir E, Tannock I. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. *J Clin Oncol* 2014; 32:3197.

Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. *Cancer* 2014; 120:3346–52.

Vera-Badillo F, Napoleone M, Ocana A, Templeton A, Seruga B, Al-Mubarak M, AlHashem H, Tannock I, Amir E. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2014; 146:235–44.

Vera-Badillo F, Escudier B, Tannock I, Knox J, Aneja P, de Gouveia P, Ocana A, Duran I, Templeton A, Amir E. Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. *Eur Urol* 2014

Templeton A, Tannock I, Tran B, Knox J, Sonpavde G, Leibowitz-Amit R, Ocana A, Aneja P, Vera-Badillo F, Seruga B, McNamara M, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* 2014; 106:dju124.

Templeton A, Tannock I, Ocana A, Seruga B, Hermanns T, Vera-Badillo F, Al-Mubarak M, McNamara M, Ace O, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2014; 23:1204-12.

Ocana A, Pandiella A, Seruga B, Cuenca-Lopez M, Diez-Gonzalez L, Corrales-Sanchez V, Templeton A, Al-Mubarak M, Vera-Badillo F, Amir E. Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. *PloS one* 2014; 9:e95219.

Al-Mubarak M, Tibau A, Templeton A, Cescon D, Ocana A, Seruga B, Amir E. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. *PloS one* 2014; 9:e88238.

Vera-Badillo F, Ocana A, Tannock I, Seruga B, Al-Mubarak M, Bedard P, Diaz-Padilla I, de Gouveia P, Templeton A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. *J Natl Cancer Inst* 2013; 106:djt319.

Vera-Badillo F, Al-Mubarak M, Templeton A, Amir E. Benefit and harms of new anti-cancer drugs. *Curr Oncol Rep* 2013; 15:270-5.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)